Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.